Pink1 suppresses α-synuclein-induced phenotypes in a Drosophila model of Parkinson's disease

Genome

Volumn 51, Issue 12, 2008, Pages 1040-1046

  Todd, Amy M ^a   Staveley, Brian E ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

synuclein; Climbing ability; Developmental defects; Drosophila; Ommatidial array; Pink1

Indexed keywords

ALPHA SYNUCLEIN; DROSOPHILA PROTEIN; PINK1 PROTEIN, DROSOPHILA; PROTEIN SERINE THREONINE KINASE;

ANIMAL; ARTICLE; CELL PROTECTION; DISEASE MODEL; DROSOPHILA; EVALUATION; EYE DISEASE; GENE THERAPY; GENETICS; HUMAN; MALE; PARKINSON DISEASE; PHENOTYPE; PHYSIOLOGY; PRENATAL DEVELOPMENT; TRANSGENIC ANIMAL;

ALPHA-SYNUCLEIN; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DROSOPHILA; DROSOPHILA PROTEINS; EYE DISEASES; GENE THERAPY; HUMANS; MALE; PARKINSON DISEASE; PHENOTYPE; PROTEIN-SERINE-THREONINE KINASES;

ANIMALIA;

EID: 57149110259     PISSN: 08312796     EISSN: None     Source Type: Journal    
DOI: 10.1139/G08-085     Document Type: Article

References (38)

1. Auluck, P.K., Chan, H.Y., Trojanowski, J.Q., Lee, V.M., and Bonini, N.M. 2002. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science, 295(5556): 865-868. doi:10.1126/science.1067389. PMID:11823645.
2. Betarbet, R., Canet-Aviles, R.M., Sherer, T.B., Mastroberardino, P.G., McLendon, C., Kim, J.H., et al. 2006. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, α-synuclein, and the ubiquitin-proteasome system. Neurobiol. Dis. 22(2): 404-420. doi:10.1016/j.nbd.2005.12.003. PMID:16439141.
3. Clark, I.E., Dodson, M.W., Jiang, C., Cao, J.H., Huh, J.R., Seol, J.H., et al. 2006. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature, 441(7097): 1162-1166. doi:10.1038/nature04779. PMID:16672981.
4. Dauer, W., Kholodilov, N., Vila, M., Trillat, A.C., Goodchild, R., Larsen, K.E., et al. 2002. Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. U.S.A. 99(22): 14524-14529. doi:10.1073/pnas.172514599. PMID:12376616.
5. Dawson, T.M., and Dawson, V.L. 2003. Molecular pathways of neurodegeneration in Parkinson's disease. Science, 302(5646): 819-822. doi:10.1126/science.1087753. PMID:14593166.
6. Exner, N., Treske, B., Paquet, D., Holmstrom, K., Schiesling, C., Gispert, S., et al. 2007. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J. Neurosci. 27(45): 12413-12418. doi:10.1523/JNEUROSCI.0719-07.2007. PMID:17989306.
7. Feany, M.B., and Bender, W.W. 2000. A Drosophila model of Parkinson's disease. Nature, 404(6776): 394-398. doi:10.1038/35006074. PMID:10746727.
8. Fornai, F., Schluter, O.M., Lenzi, P., Gesi, M., Ruffoli, R., Ferrucci, M., et al. 2005. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and α-synuclein. Proc. Natl. Acad. Sci. U.S.A. 102(9): 3413-3418. doi:10.1073/pnas.0409713102. PMID:15716361.
9. Freeman, M. 1996. Reiterative use of the EGF receptor triggers differentiation of all cell types in the Drosophila eye. Cell, 87(4): 651-660. doi:10.1016/S0092-8674(00)81385-9. PMID:8929534.
10. Gasser, T. 2007. Update on the genetics of Parkinson's disease. Mov. Disord. 22(S17): S343-S350. doi:10.1002/mds.21676.
11. Haque, M.E., Thomas, K.J., D'Souza, C., Callaghan, S., Kitada, T., Slack, R.S., et al. 2008. Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP. Proc. Natl. Acad. Sci. U.S.A. 105(5): 1716-1721. doi:10.1073/pnas.0705363105. PMID:18218782.
12. Haywood, A.F., and Staveley, B.E. 2004. parkin counteracts symptoms in a Drosophila model of Parkinson's disease. BMC Neurosci. 5: 14. doi:10.1186/1471-2202-5-14. PMID:15090075.
13. Hoepken, H.H., Gispert, S., Morales, B., Wingerter, O., Del Turco, D., Mulsch, A., et al. 2007. Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6. Neurobiol. Dis. 25(2): 401-411. doi:10.1016/j.nbd.2006.10.007. PMID:17141510.
14. Hsu, L.J., Sagara, Y., Arroyo, A., Rockenstein, E., Sisk, A., Mallory, M., et al. 2000. α-Synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 157(2): 401-410. PMID:10934145.
15. Ibanez, P., Bonnet, A.M., Debarges, B., Lohmann, E., Tison, F., Pollak, P., et al. 2004. Causal relation between α-synuclein gene duplication and familial Parkinson's disease. Lancet, 364(9440): 1169-1171. doi:10.1016/S0140-6736(04)17104-3. PMID:15451225.
16. Klivenyi, P., Siwek, D., Gardian, G., Yang, L., Starkov, A., Cleren, C., et al. 2006. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol. Dis. 21(3): 541-548. doi:10.1016/j.nbd.2005.08.018. PMID:16298531.
17. Kramer, J.M., and Staveley, B.E. 2003. GAL4 causes developmental defects and apoptosis when expressed in the developing eye of Drosophila melanogaster. Genet. Mol. Res. 2(1): 43-47. PMID:12917801.
18. Le Bourg, E., and Lints, F.A. 1992. Hypergravity and aging in Drosophila melanogaster. 4. Climbing activity. Gerontology, 38(1-2): 59-64. PMID:1612462.
19. Li, H., Chaney, S., Roberts, I.J., Forte, M., and Hirsh, J. 2000. Ectopic G-protein expression in dopamine and serotonin neurons blocks cocaine sensitization in Drosophila melanogaster. Curr. Biol. 10(4): 211-214. doi:10.1016/S0960-9822(00)00340-7. PMID:10704417.
20. Martin, L.J., Pan, Y., Price, A.C., Sterling, W., Copeland, N.G., Jenkins, N.A., et al. 2006. Parkinson's disease α-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. 26(1): 41-50. doi:10.1523/JNEUROSCI.4308-05.2006. PMID:16399671.
21. Mukaetova-Ladinska, E.B., and McKeith, I.G. 2006. Pathophysiology of synuclein aggregation in Lewy body disease. Mech. Ageing Dev. 127(2): 188-202. doi:10.1016/j.mad.2005.09.014. PMID:16297436.
22. Park, J., Lee, S.B., Lee, S., Kim, Y., Song, S., Kim, S., et al. 2006. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature, 441(7097): 1157-1161. doi:10.1038/nature04788. PMID:16672980.
23. Petit, A., Kawarai, T., Paitel, E., Sanjo, N., Maj, M., Scheid, M., et al. 2005. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. J. Biol. Chem. 280(40): 34025-34032. doi:10.1074/jbc.M505143200. PMID:16079129.
24. Plun-Favreau, H., Klupsch, K., Moisoi, N., Gandhi, S., Kjaer, S., Frith, D., et al. 2007. The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat. Cell Biol. 9(11): 1243-1252. doi:10.1038/ncb1644. PMID:17906618.
25. Poole, A.C., Thomas, R.E., Andrews, L.A., McBride, H.M., Whitworth, A.J., and Pallanck, L.J. 2008. The PINK1/Parkin pathway regulates mitochondrial morphology. Proc. Natl. Acad. Sci. U.S.A. 105(5): 1638-1643. doi:10.1073/pnas.0709336105. PMID:18230723.
26. Pridgeon, J.W., Olzmann, J.A., Chin, L.S., and Li, L. 2007. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol. 5(7): e172. doi:10.1371/journal.pbio.0050172. PMID:17579517.
27. Rubin, G.M., Hong, L., Brokstein, P., Evans-Holm, M., Frise, E., Stapleton, M., and Harvey, D.A. 2000. A Drosophila complementary DNA resource. Science, 287(5461): 2222-2224. doi:10.1126/science.287.5461. 2222. PMID:10731138.
28. Schapira, A.H. 2008. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol. 7(1): 97-109. doi:10.1016/S1474- 4422(07)70327-7. PMID:18093566.
29. Staveley, B.E., Phillips, J.P., and Hilliker, A.J. 1990. Phenotypic consequences of copper-zinc superoxide dismutase overexpression in Drosophila melanogaster. Genome, 33(6): 867-872. doi:10.1139/g90-130. PMID:1964925.
30. Todd, A.M., and Staveley, B.E. 2004. Novel assay and analysis for measuring climbing ability in Drosophila. Drosoph. Inf. Serv. 87: 101-107.
31. Valente, E.M., Abou-Sleiman, P.M., Caputo, V., Muqit, M.M., Harvey, K., Gispert, S., et al. 2004a. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science, 304(5674): 1158-1160. doi:10.1126/science.1096284. PMID:15087508.
32. Valente, E.M., Salvi, S., Ialongo, T., Marongiu, R., Elia, A.E., Caputo, V., et al. 2004b. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann. Neurol. 56(3): 336-341. doi:10.1002/ana.20256. PMID:15349860.
33. Volles, M.J., Lee, S.J., Rochet, J.C., Shtilerman, M.D., Ding, T.T., Kessler, J.C., and Lansbury, P.T., Jr. 2001. Vesicle permeabilization by protofibrillar α-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry, 40(26): 7812-7819. doi:10.1021/bi0102398. PMID:11425308.
34. Wang, H.L., Chou, A.H., Yeh, T.H., Li, A.H., Chen, Y.L., Kuo, Y.L., et al. 2007. PINK1 mutants associated with recessive Parkinson's disease are defective in inhibiting mitochondrial release of cytochrome c. Neurobiol. Dis. 28(2): 216-226. doi:10.1016/j.nbd.2007.07.010. PMID:17707122.
35. Weintraub, D., Comella, C.L., and Horn, S. 2008. Parkinson's disease - Part 1: pathophysiology, symptoms, burden, diagnosis, and assessment. Am. J. Manag. Care, 14(2 Suppl.): S40-S48. PMID:18402507.
36. Whitworth, A.J., Wes, P.D., and Pallanck, L.J. 2006. Drosophila models pioneer a new approach to drug discovery for Parkinson's disease. Drug Discov. Today, 11(3-4): 119-126. doi:10.1016/S1359-6446(05)03693-7. PMID:16533709.
37. Wood-Kaczmar, A., Gandhi, S., Yao, Z., Abramov, A.S., Miljan, E.A., Keen, G., et al. 2008. PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. PLoS One, 3(6): e2455. doi:10.1371/journal.pone. 0002455. PMID:18560593.
38. Yang, Y., Gehrke, S., Imai, Y., Huang, Z., Ouyang, Y., Wang, J.W., et al. 2006. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc. Natl. Acad. Sci. U.S.A. 103(28): 10793-10798. doi:10.1073/pnas. 0602493103. PMID:16818890.